News Column

TerraBioGen Closes Private Placement

June 11, 2014



VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 11, 2014) - TerraBioGen Technologies Inc., a developer of proprietary high-value agriculturally bioactive products, announces that it has closed a private placement.

The private placement is for 21,000 units at $10.00 per unit for proceeds of $210,000. Each unit consists of one common share and one warrant exercisable at $12.00 per share for 5 years.

These funds will be used for the Company's 2014 growing trials on a wide range of crops and to continue research and development activities.

About TerraBioGen

TerraBioGen Technologies Inc. is committed to research and development to continue to improve the efficiency of its technology, its methodology, and the quality of its agricultural products. It is further committed to developing a world-wide marketing capability to ensure market acceptance of its products.

This news release contains certain statements that may be deemed "forward-looking" statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although TerraBioGen believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward looking statements are based on the beliefs, estimates and opinions of TerraBioGen's management on the date the statements are made. Except as required by law, TerraBioGen undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

THIS PRESS RELEASE, REQUIRED BY APPLICABLE CANADIAN LAWS, IS NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN. THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO U.S. PERSONS UNLESS REGISTERED OR EXEMPT THEREFROM.

FOR FURTHER INFORMATION PLEASE CONTACT: Blair Heffelfinger President & CEO TerraBioGen Technologies Inc.bheffelfinger@terrabiogen.com (604) 444-1023 ext 316 (604) 444-1043 fax Bob Nowell CFO & Corporate Secretary TerraBioGen Technologies Inc.bnowell@terrabiogen.com (604) 444-1023 ext 306 (604) 444-1043 fax Source: TerraBioGen Technologies Inc.


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Marketwire (Canada)


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters